MedTech Strategist Issue: Vol. 6, No. 5 - April 3, 2019


Already a Subscriber?


Not a Subscriber?

Gender Diversity - “Biodesign Bridges the Gender Gap”

By David Cassak, Co-Editor-in-Chief

Despite the central role they play in healthcare decisions in this country, women are vastly underrepresented in key decision-making positions in the healthcare industry, and medtech is no exception. Having identified a gender gap within its own program, officials of Stanford’s Biodesign have embarked on an initiative to eliminate the gender gap and bring women into a more key role in the program and the larger medtech industry.

Gener Diversity.jpg


Diabetes - “Technology Advances Redefine the Standard of Care”

By Mary Thompson, Executive Editor

The diabetes device market continues its high-tech transformation, as companies work to roll out new, more patient-friendly devices. Alliances in diabetes increasingly involve a wide variety of stakeholders.

Regenerative Medicine - “Farshid Guilak is Betting 3D Biofabrics, Smart Cells, and Drug-Device Combinations Can Fight Osteoarthritis”

By Wendy Diller, Senior Writer/Market Analyst

Beyond the hype, we know a lot more about controlling stem cell behavior and advanced biomaterials that could lead to new tools for soft tissue regeneration and osteoarthritis, says Washington University’s Farshid Guilak. Part two of a three-part series.



Outside Opinion - “Can Innovative Value-Based Pricing Models Relieve Pricing Pressure in the Medical Device Industry?”

By Matthew Majewski and Kira Gordon, Contributing Writers, CRA

Hospital consolidation is increasing purchasing leverage through greater pricing transparency and that has substantiated a need for new pricing models in medtech. There are challenges associated with several emerging pricing models; regardless, manufacturers will need to develop innovative approaches to maximize opportunity while minimizing risk.

Heart Failure - “Reprieve Cardiovascular: Improving the Front-Line therapy for Acute Decompensated Heart Failure”

By Mary Stuart, Senior Writer/Market Analyst

Reprieve Cardiovascular’s Guided Diuretic Therapy for fluid overload optimizes diuretics, today’s front-line therapy for acute decompensated heart failure, in a way that promises to be faster, safer, and, in the long run, more helpful for patient management than drugs on their own.

Heart Failure. 3-13-19jpg.jpg


Neurovascular - “Vasotorq: Catching Clots Quicker”

By Colin Miller, Contributing Writer

Current thrombectomy devices for the treatment of ischemic stroke can require several passes through the vasculature to extract sufficient clot material, often leaving behind up to 20%. That robs surgeons of valuable time and increases their fatigue. With a patented stent with distal protection, early-stage Vasotorq aims to more efficiently collect thrombi on the first pass to improve the standard of stroke care.

Not a Subscriber?

Already a Subscriber?

Want a Sample Article?

Companies Covered in this Issue: Abbott Laboratories Inc., Aetna Inc., Beta Bionics Inc., Bigfoot Biomedical, CeQur Corp., CHF Solutions Inc., Cytex Therapeutics Inc., DexCom Inc., Diabeloop AP, Eli Lilly & Co., EOFlow Inc., Glooko Inc., IBM Watson Health, Insulet Corp., Johnson & Johnson, Mannkind Corp., Medtronic PLC, Novartis AG, Novo Nordisk AS, Osiris Therapeutics Inc., Pfizer Inc., RenalGuard Solutions Inc., Reprieve Cardiovascular Inc., Roche Diabetes Care, Sanofi, Senseonics Holdings Inc., Sensile Medical AG, Smith & Nephew PLC, Stryker Corp., Tandem Diabetes Care Inc., Tidepool, UnitedHealthcare, Valeritas Holdings Inc., Vasotorq Inc., Verily Life Sciences Inc., Vicentra BV

Topics Covered in this Issue: Business Strategies; Cardiovascular/Vascular; Diabetes; Digital Health; Executive Interviews; Neurology/Neurovascular; Orthopedics/Spine; Providers & Payors; Regenerative Medicine/Cell Therapy; Start-Ups to Watch; Perspective/Commentary